Avantium has raised US$33.6m via an accelerated bookbuild offering
Avantium N.V. has raised US$33.6 million through an accelerated bookbuild offering of 5,206,589 new ordinary shares, representing approximately 19.99% of the company’s issued share capital. The shares have been placed at a price of US$6.42 (€5.35) per new ordinary share.
Avantium, founded in 2000 and headquartered in Amsterdam, is a leading technology development company and a forerunner in renewable chemistry. Together with its partners around the world, the company focuses on developing and commercializing breakthrough technologies for the production of chemicals from renewable sources and circular plastic materials used for a variety of consumer products. In addition, the company also provides advanced catalysis R&D services and systems to clients active in the refinery and chemical industries.
In January 2020, Avantium signed a letter of intent regarding its new FDCA flagship plant in Delfzijl, the Netherlands, for which it has currently signed five conditional offtake agreements for over 50% of its production capacity. The world’s first commercial FDCA plant will produce plant-based FDCA, a key building block for many chemicals and plastics such as PEF. The US$33.6 million capital increase marks an important step for Avantium towards a positive final investment decision for the construction of the plant.
Oaklins’ team in the Netherlands acted as financial advisor to Avantium and raised over 17% of pre-commitments.
Tom van Aken
CEO, Avantium N.V.
Talk to the deal team
Related deals
Tekova Oyj has completed a technical listing on the Nasdaq First North Growth Market Finland
Tekova Oyj has successfully completed a technical listing (IPO) on the Nasdaq First North Growth Market Finland. This transaction marks a significant milestone in the company’s growth strategy, enhancing its visibility and access to capital markets.
Learn moreDuke Capital Limited has completed a fundraising
Duke Capital Limited has completed a successful fundraise, securing US$29.8 million (£23.5 million) through a placing and retail offer on the Alternative Investment Market (AIM). This milestone will further enable Duke Capital to continue its innovative approach to alternative financing solutions for small and medium enterprises (SMEs) across the UK and Europe.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more